Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer (SIRB2)

Fujian Provincial Cancer Hospital

Status and phase

Withdrawn

Phase 1

Conditions

Metastatic Colorectal Cancer

Treatments

Drug: Irinotecan

Drug: S-1

Drug: Bevacizumab

Study type

Interventional

Funder types

Other

Identifiers

NCT03380689

FNF008

Details and patient eligibility

About

Phase I Study of biweekly combination therapy with S-1, Irinotecan, and Bevacizumab as 1-line Chemotherapy in Patients With Advanced Colorectal Cancer.

Full description

In several clinical studies from Japan and South Korea, the combination regimen of S-1 and irinotecan has shown efficacy in the treatment of advanced colorectal cancer, and a Phase III study（TRICOLORE） showed that the combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) is not inferior to the oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy. Here, we design this phase I study to explore the Chinese population's tolerability and efficacy of Biweekly SIRB Regimen(S-1/irinotecan/bevacizumab) and to explore the recommended dose of irinotecan in this regimen.

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically confirmed colorectal carcinoma with inoperable, locally advanced, or metastatic disease, not amenable to curative therapy
Measurable disease or non-measurable but assessable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)
Patients with no previous treatment (radiotherapy or chemotherapy). Patients who have received postoperative adjuvant chemotherapy are eligible if relapse is diagnosed more than 180 days after the end of such treatment.
Age ≥20 years
Life expectancy of at least 3 months
ECOG PS of 0 or 1
Adequate function of major organs as defined below:
- Hemoglobin ≥9.0g/dL
- White blood cell count ≥3,500/mm3
- Neutrophil count ≥1,500/mm3
- Platelet count ≥100,000/mm3
- AST and ALT ≤100 U/L (<200 U/L in patients with liver metastasis)
- Serum creatinine ≤1.2 mg/dL
  - Creatinine clearance estimate by the Cockcroft-Gault method >50 mL/min (reduce initial dosage by one step if ≥50 but <80 mL/min)
Able to take capsules orally.
No electrocardiographic abnormalities within 28 days before enrollment that would clinically preclude the execution of the study, as judged by the investigator.
Voluntary written informed consent.

Exclusion criteria

Serious drug hypersensitivity or a history of drug allergy
Active double cancer
Active infections (e.g., patients with pyrexia of 38℃ or higher)
History of gastrointestinal perforation, intestinal tract paralysis, or ileus within 1 year.
Uncontrolled hypertension
Serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart failure, renal failure, hepatic failure, or poorly controlled diabetes)
Moderate or severe ascites or pleural effusion requiring treatment
Watery diarrhea
Treatment with flucytosine or atazanavir sulfate
Metastasis to the CNS
Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing mothers. Men who are currently attempting to conceive children.
Severe mental disorder
Continuous treatment with steroids
Urine dipstick for proteinuria should be <2+
Patient with a past history of thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism
Major surgical procedure, open biopsy, or clinically significant traumatic injury within 4 weeks
Long-term daily treatment with aspirin (>325 mg/day)
History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
Judged ineligible for participation in the study by the investigator for safety reasons.